Illumina (ILMN +1%) agrees to dismiss all claims against Complete Genomics, a wholly-owned subsidiary of BGI-Shenzhen, saying it's entered into a settlement agreement under which it will dismiss both lawsuits it had filed. Complete Genomics, in turn, will dismiss all counterclaims, with each party bearing its own litigation costs. No payment is being made by either party to the other, and no licenses are being granted by either party to the other.
Illumina (ILMN +1%) agrees to dismiss all claims against Complete Genomics, a wholly-owned...
From other sites
Video at CNBC.com (Jun 28, 2016)
Video at CNBC.com (Apr 19, 2016)
Video at CNBC.com (Oct 6, 2015)
at CNBC.com (Jan 9, 2015)
at CNBC.com (Dec 29, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs